AML patients with DNMT3A R882 mutation have an adverse outcome by promoting resistance to anthracycline chemotherapy via impaired nucleosome remodeling [5], and the frequency of DNMT3A mutant hematopoietic stem cells (HSCs) in AML patients increases gradually from diagnosis to relapse [6], suggesting that DNMT3A mutant cells survive chemotherapy and drive relapse. This evidence concerns the gene DNMT3A and acute myeloid leukemia.